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Letters to the editor
Radiation pneumonitis after local-
regional radiotherapy following
autologous stem-cell transplant
for high-risk breast cancer
We have read the article by Moore et al. [1] regarding the
toxicity and outcome of high-dose chemotherapy with stem-
cell support followed by local and regional radiotherapy in a
cohort of 103 patients with high-risk breast cancer. Radiation
therapy to the breast (or chest wall) plus regional lymph node
areas is aimed at decreasing the unacceptably high rate of
loco-regional relapses (33% in Peter's report [2]) seen in
patients with metastasis to > 10 axillary lymph nodes after
surgery plus high-dose chemotherapy. Indeed, it significantly
decreases the rate of loco-regional relapses in this patient
population, as shown by Moore et al. [1]. However this is
achieved at the cost of substantial toxicity for some patients.
We have recently analyzed the toxicities of local-regional
radiotherapy following high dose chemotherapy with carbo-
platin, tiothepa and cyclophosphamide [3] with autologous
stem-cell transplant in a cohort of 31 patients with high-risk
breast cancer (>10 axillary nodes: 7 patients; 4-9 nodes: 7
patients or stage III: 17 patients). All patients received the
scheduled dose of radiation (electron beam: 5500 cGy to the
breast or chest wall, and 4500 cGy to the axillary, supra-
clavicular and internal mammary lymph node areas) relatively
early after transplant (median time from stem-cell infusion to
initiation of radiotherapy: 49 days, range 19-84 days; median
duration of radiotherapy: 43 days, range 36-54 days), and only
five patients (16%) required temporary discontinuation of
radiation for one to two weeks following mild fever of unknown
origin (3 patients) and acute pneumonitis (2 patients). Radiation
pneumonitis was a frequent toxicity in this series. Ten patients
(32%) had acute pneumonitis. Dry cough and fever were the
presenting symptoms. Most patients underwent an unsuccess-
ful work-up for infectious pneumonia often including admis-
sion. The symptoms subsided with corticosteroid therapy.
We feel it should be emphasized that radiation pneumonia
is a frequent cause of fever in patients with high-risk breast
cancer undergoing local-regional radiation therapy after high-
dose chemotherapy with stem-cell support.
J. L. Marti, A. Tres, CVelilla, P. Lopez, M. D. Garcia,
D. Isla & J. I. Mayordomo
Division of Medical Oncology, University Hospital,
Zaragoza, Spain
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Urinary bladder cancer death rates
in Europe
Several risk factors have been associated with bladder cancer
risk, including cigarette smoking, occupational exposure to
aromatic amines and other chemicals, bladder infections, se-
lected aspects of diet, and the use of some drugs such as
phenacetine-containing analgesics, chlornaphazine and cyclo-
phosphamide [1]. In the US [2], Britain [3] and Italy [4] 50°/<r-
70% of bladder cancers in men, and 20%-35% in women were
attributable to cigarette smoking, and 5%-10% to occupa-
tional exposures. Changes in exposure to these two major risk
factors, therefore, may largely explain trends registered in
mortality from the disease, mostly for males.
In 1990-1994, most of the age-adjusted (world standard
population) mortality rates for men in Europe ranged between
5 and 8 per 100,000. Only Denmark (8.9), Spain and Italy (8.6),
and Hungary (8.1) had rates over 8/100,000. Sweden and other
Nordic countries had low rates. Rates for women were between
1 and 3/100,000 in most European countries [5, 6]. An age-
period and cohort model showed that in most western Europe
mortality increased up to the generations born around 1920 to
1940, and declined thereafter [7]. In the United States, the
declines had started earlier, and bladder cancer mortality has
been declining in white and black populations of both sexes
since the late 1970s [8].
Figure 1 gives trends in age-standardized (world standard)
all age and truncated 35-64 years bladder cancer mortality
from 1955 to 1994 in the European Union, derived from the
World Health Organisation database [9, 10]. Overall age-
standardized rates in males increased from 4.5/100,000 in
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Figure I. Trends in age-standardized (per 100.000. world standard)
mortality rates from bladder cancer in the 15 countries of the European
Union, 1955-1996.
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Figure 2 Trends in age-standardized (per 100,000, world standard)
mortality rates from bladder cancer in six eastern European countries,
1955-1996
1955-1959 to 7.4 in 1985-1989, and levelled off thereafter to
6.4/100,000 in 1995-1996. Truncated rates were 5.4/100,000
males in 1955-1959, peaked at 6.5 in 1980-1984, and declined
to 4.6/100,000 males in 1995-1996. For females, overall rates
increased from 1.4/100,000 in 1955-1959 to 1.6 in 1985-1989,
and remained approximately stable thereafter. Truncated rates
in females remained around 1.4/100,000 between 1955 and 1980,
and declined thereafter to reach 1.1/100,000 in 1995-1996.
Corresponding values for six eastern European countries
providing data (Bulgaria, Hungary, Poland, Romania, Czech
Republic, Slovakia, i.e., former Czechoslovakia) are given in
Figure 2. Overall bladder cancer rates for males in eastern
European countries rose from 4.9 in 1955-1959 to 7.1/100,000 in
1995-1996. Truncated rates declined from 6.5/100,000 in 1955-
1959 to 5.2/100,000 in 1970-1974, but steadily increased there-
after to reach 7.5/100,000 in 1995-1996. In females, overall rates
slightly increased from the early 1970s (1.0/100,000) to reach 1.3/
100,000 in the mid-1990s. Truncated rates, after a decline
between the mid 1950s (1.6/100,000 females) and the early 1970s
(1.0/100,000), remained around 1.2/100,000 until the mid 1990s.
The present figures indicate that bladder cancer mortality
has started to decline for males in the European Union about
ten years later than in the United States. In Eastern Europe, in
contrast, bladder cancer mortality is still appreciably upwards
in males, is now higher than in the European Union, and has
started to rise in females, too. This indicates that there were
substantial delays in controlling major risk factors for bladder
cancer in these countries, mainly tobacco and occupational
exposure to carcinogens [9. 10].
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Elevation of urinary porphyrin levels
following gemcitabine administration
A 67-year-old man with a diagnosis of porphyria cutanea tarda
(PCT) and HCV-positive well compensated (Child-Pugh A)
liver cirrhosis came to our institution because of ultrasono-
graphic evidence of a 4 cm liver lesion, discovered during a
routine examination. Cytologic examination of a fine-needle
biopsy (FNAB) of this lesion was suggestive of adenocarcino-
ma. A laparotomy showed diffuse abdominal adenomegalies.
Histologic examination of an intraoperatory liver mass biopsy
and a resected retroperitoneal lymph node showed the presence
of a metastatic cholangiocarcinoma. After an uneventful post-
operative recovery, the patient agreed to participate in an
investigational protocol with gemcitabine that was adminis-
tered at the dosage of 1.000 mg/m2 on days 1, 8 and 15,
repeated every 28 days. Twenty-four to seventy-two hours after
each administration, the patient noticed dark urine. Urine
examination was negative for the presence of blood or biliary
pigments. Before the second chemotherapy cycle, the assay for
total urinary1 porphyrins was within normal values (78 ug/1.
normal range 50-200 ug/1). A new assay performed on urine
collected 48 hours after the first administration of the second
